Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage…
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
September 03, 2025 21:47 ET | Source: Mesoblast Limited NEW YORK, Sept.…
Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies
Collaboration in Singapore aims to further expand the broad potential of Life…
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal…
Celularity Receives Nasdaq Notice Regarding Form 10-Q
May 30, 2025 17:30 ET | Source: Celularity Inc. FLORHAM PARK, N.J.,…